ATE149791T1 - Verfahren und zusammensetzungen zur behandlung von pathologischen hydrophoben interaktionen in biologischen flüssigkeiten - Google Patents

Verfahren und zusammensetzungen zur behandlung von pathologischen hydrophoben interaktionen in biologischen flüssigkeiten

Info

Publication number
ATE149791T1
ATE149791T1 AT90901954T AT90901954T ATE149791T1 AT E149791 T1 ATE149791 T1 AT E149791T1 AT 90901954 T AT90901954 T AT 90901954T AT 90901954 T AT90901954 T AT 90901954T AT E149791 T1 ATE149791 T1 AT E149791T1
Authority
AT
Austria
Prior art keywords
c2h4o
surface active
compositions
methods
present
Prior art date
Application number
AT90901954T
Other languages
English (en)
Inventor
Robert L Hunter
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE149791T1 publication Critical patent/ATE149791T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/13—Burn treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT90901954T 1988-12-29 1989-12-28 Verfahren und zusammensetzungen zur behandlung von pathologischen hydrophoben interaktionen in biologischen flüssigkeiten ATE149791T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/291,925 US4879109A (en) 1986-05-15 1988-12-29 Method for treating burns

Publications (1)

Publication Number Publication Date
ATE149791T1 true ATE149791T1 (de) 1997-03-15

Family

ID=23122462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90901954T ATE149791T1 (de) 1988-12-29 1989-12-28 Verfahren und zusammensetzungen zur behandlung von pathologischen hydrophoben interaktionen in biologischen flüssigkeiten

Country Status (13)

Country Link
US (1) US4879109A (de)
EP (1) EP0409940B1 (de)
JP (1) JP2554396B2 (de)
AT (1) ATE149791T1 (de)
AU (1) AU637996B2 (de)
CA (1) CA2006953C (de)
DE (1) DE68927859T2 (de)
DK (1) DK194690A (de)
ES (1) ES2099094T3 (de)
FI (1) FI904254A0 (de)
HU (1) HU205858B (de)
NO (1) NO903775L (de)
WO (1) WO1990007336A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648071A (en) * 1986-05-15 1997-07-15 Emory University Method of treating tumors
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
US5681576A (en) * 1988-11-16 1997-10-28 Mdv Technologies, Inc. Method and composition for post surgical adhesion reduction
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
US5073171A (en) * 1989-01-12 1991-12-17 Eaton John W Biocompatible materials comprising albumin-binding dyes
JPH0776175B2 (ja) * 1990-04-26 1995-08-16 サイトアーレクス・コーポレーシヨン 損傷されたかまたは病気になった組織の局所的処置用の組成物および方法
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US5306501A (en) * 1990-05-01 1994-04-26 Mediventures, Inc. Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5593683A (en) * 1990-05-01 1997-01-14 Mdv Technologies, Inc. Method of making thermoreversible polyoxyalkylene gels
CA2040460C (en) * 1990-05-01 1997-06-10 Tacey X. Viegas Drug delivery with thermoreversible gels
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5847023A (en) * 1990-10-26 1998-12-08 Mdv Technologies, Inc. Thermal irreversible gel corneal contact lens formed in situ
US5696298A (en) * 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US6933286B2 (en) 1991-03-19 2005-08-23 R. Martin Emanuele Therapeutic delivery compositions and methods of use thereof
US7202225B1 (en) 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
USRE38558E1 (en) 1991-03-19 2004-07-20 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
US5605687A (en) * 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
GB9221883D0 (en) * 1992-10-19 1992-12-02 Wellcome Found Novel formulation
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5783178A (en) * 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5843470A (en) * 1995-10-06 1998-12-01 Mdv Technologies, Inc. Method and composition for inhibiting post-surgical adhesions
US5952392A (en) * 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US6596401B1 (en) 1998-11-10 2003-07-22 C. R. Bard Inc. Silane copolymer compositions containing active agents
US6579539B2 (en) 1999-12-22 2003-06-17 C. R. Bard, Inc. Dual mode antimicrobial compositions
US6780648B1 (en) * 2000-09-20 2004-08-24 General Electric Company Method and system for selectively distributing luminescence material precursors
CA2421026C (en) * 2001-10-16 2005-02-15 Avanir Pharmaceuticals Viral inhibition by n-docosanol
US20040101507A1 (en) * 2002-11-27 2004-05-27 Janco Predovan Skin cream
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
US20060009522A1 (en) * 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
CA2584138A1 (en) * 2004-10-18 2006-04-27 Raphael C. Lee Methods and compositions for treatment of free radical injury
CA2660928A1 (en) * 2006-08-18 2008-02-28 Regenerx Biopharmaceuticals, Inc. Methods and compositions for conserving and/or preparing an organ or tissue for transplant
AU2008287419A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases
BR112013011858A2 (pt) 2010-11-15 2017-03-21 Mast Therapeutics Inc métodos para reforçar oxigenação de tecido comprometido
US20160235781A1 (en) 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
EP3166617B1 (de) 2014-07-07 2024-01-10 LifeRaft Biosciences, Inc. Poloxamer zusammensetzung frei von lang zirkulierendem material, methoden zur herstellung und verwendungen
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3450502A (en) * 1967-09-25 1969-06-17 Wyandotte Chemicals Corp Method of operating heart-lung apparatus
US3639575A (en) * 1968-06-19 1972-02-01 Basf Wyandotte Corp Silver ion gel compositions and method of using the same
US3641240A (en) * 1968-09-27 1972-02-08 Wyandotte Chemicals Corp Method for the treatment of an embolus or thrombus
US3590125A (en) * 1969-10-10 1971-06-29 Wyandotte Chemicals Corp Physiological salt solutions of ethylene oxide-polypropylene glycol condensation products as blood plasma substitutes
US3577522A (en) * 1969-10-10 1971-05-04 Wyandotte Chemicals Corp Methods for the treatment of shock with ethylene oxide-polypropylene glycol condensates as blood plasma substitutes
US3980772A (en) * 1969-12-02 1976-09-14 Baxter Laboratories, Inc. Methods of dissolving blood clots and the like with streptokinase chemically bonded to a carbohydrate matrix
US3867521A (en) * 1970-08-26 1975-02-18 Scherer Corp R P Method for absorption of drugs
US4073886A (en) * 1973-01-30 1978-02-14 Baxter Travenol Laboratories, Inc. Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene
US3956259A (en) * 1973-01-30 1976-05-11 Baxter Laboratories, Inc. Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate
US3997458A (en) * 1974-04-12 1976-12-14 Deknatel, Incorporated Method of cleansing contaminated wounds and surgical scrub solutions for same
US4086218A (en) * 1975-04-11 1978-04-25 Edward Shanbrom, Inc. Method of preserving blood plasma II
US4186253A (en) * 1978-10-10 1980-01-29 The Green Cross Corporation Perfusate for preserving organ to be transplanted and preserving method
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
CA1244774A (en) * 1983-11-09 1988-11-15 Thomas Jefferson University Medium for storing blood platelets
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
WO1987006836A1 (en) * 1986-05-15 1987-11-19 Emory University Fibrinolytic composition
AU6334586A (en) * 1986-05-15 1987-12-01 Emory University Composition and method for treating a thrombus and embolus

Also Published As

Publication number Publication date
HU205858B (en) 1992-07-28
AU4849590A (en) 1990-08-01
CA2006953A1 (en) 1990-06-29
NO903775D0 (no) 1990-08-28
ES2099094T3 (es) 1997-05-16
FI904254A0 (fi) 1990-08-29
AU637996B2 (en) 1993-06-17
DK194690D0 (da) 1990-08-15
EP0409940A1 (de) 1991-01-30
DK194690A (da) 1990-10-22
DE68927859T2 (de) 1997-08-07
NO903775L (no) 1990-10-22
WO1990007336A1 (en) 1990-07-12
JPH03505879A (ja) 1991-12-19
EP0409940A4 (en) 1993-01-27
JP2554396B2 (ja) 1996-11-13
US4879109A (en) 1989-11-07
EP0409940B1 (de) 1997-03-12
DE68927859D1 (de) 1997-04-17
HU901138D0 (en) 1991-03-28
CA2006953C (en) 2000-10-03

Similar Documents

Publication Publication Date Title
ATE149791T1 (de) Verfahren und zusammensetzungen zur behandlung von pathologischen hydrophoben interaktionen in biologischen flüssigkeiten
PE41696A1 (es) Agente antitrombotico
DE69322624T2 (de) Präparat zur behandlung und verhütung von bakteriellen infektionen,das chlordioxyd enthalt
ATE4723T1 (de) Silicium-polyaether-copolymere, verfahren zu deren herstellung, zusammensetzungen fuer die behandlung von textilmaterialien und die so behandelten, beschichteten materialien.
DE69011460D1 (de) Bakteriocine enthaltende zusammensetzungen zur verwendung als verbesserte breitspektrum-bakterizide und verfahren zur verhütung und behandlung von mikrobiellen infektionen.
DE69023650D1 (de) Verfahren zur behandlung eines porösen substrats zwecks erhaltung von verbesserten wasser- und ölabweisenden eigenschaften.
BR9509636A (pt) Compostos anfifílicos com pelo menos dois grupos hidrófilos e pelo menos dois grupos hidrófobos à base de amidas
DK131587D0 (da) Phospholipidholdige oploesninger
ATE183098T1 (de) Entfernung von antikörpern aus von blut stammenden zusammensetzungen unter erhalt von gerinnungsfaktoren
NO913684L (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
DE59108407D1 (de) Galactomannanderivate zur Umhüllung oder Einbettung von Arzneimittelwirkstoffen
FR2469711A1 (fr) Immunopotentialisateur contenant de la ricine et composition therapeutique le contenant
ATE128176T1 (de) Verfahren zur antimikrobiellen konservierung von tensiden.
NO913683L (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
SU1666683A1 (ru) Бактерицид
JPS6357502A (ja) 手指消毒用組成物
US3100235A (en) Preservation of rubber latex
FR2643368B1 (fr) Nouveaux derives du glycerol, leur procede de preparation, compositions reticulantes en contenant, et leur utilisation dans l'industrie textile
KR920700068A (ko) 음이온 교환체 및 유체의 처리방법
KR910004097A (ko) 식물체의 생리장해 방지 조성물 및 그를 이용한 방법
KR20050033738A (ko) 비린내가 저감된 키틴 키토산 함유 고등어
KR960030949A (ko) 신규 지혈제 조성물
DE3407026A1 (de) Zur behandlung von erkrankungen des analbereichs

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee